Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Prelude Therapeutics Inc | Chief Financial Officer | Common Stock | 42.2K | $159K | $3.77 | May 23, 2023 | Direct |
Prelude Therapeutics Inc | Chief Financial Officer | Employee Stock Option (right to buy) | 150K | Mar 1, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PRLD | Prelude Therapeutics Inc | Mar 1, 2024 | 1 | $0 | 4 | Mar 4, 2024 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | May 23, 2023 | 1 | $27.5K | 4 | May 25, 2023 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Feb 7, 2023 | 1 | $0 | 4 | Feb 9, 2023 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Dec 21, 2022 | 1 | $0 | 4 | Dec 22, 2022 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Dec 8, 2022 | 1 | $47.6K | 4 | Dec 12, 2022 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Jun 1, 2022 | 1 | $42.3K | 4 | Jun 1, 2022 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Mar 21, 2022 | 1 | $48.8K | 4 | Mar 22, 2022 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Feb 15, 2022 | 1 | $0 | 4 | Feb 17, 2022 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Dec 13, 2021 | 1 | $61.4K | 4 | Dec 14, 2021 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Nov 29, 2021 | 1 | $0 | 4 | Dec 1, 2021 | Chief Financial Officer |
PRLD | Prelude Therapeutics Inc | Nov 29, 2021 | 0 | $0 | 3 | Dec 1, 2021 | Chief Financial Officer |